Aortic surgery guidelines vs COAPT Risk Score

Aorta was developed as a collaboration between Consultant Cardiac Surgeons Yoan Lamarche, MD, FRCSC, Ismail El-Hamamsy, MD, PhD, FRCSC and Philippe Demers, MD, FRCSC from the Montreal Heart Institute (Montreal, Canada) and app development company SolidByte Inc. This was made possible by a development grant from the Department of Surgery of the Université de Montréal. Aorta provides the guidelines recommendation based on a set of easy data entry points, which the user simply needs to fill out. The app then combines all the elements and informs the clinician about the presence or absence of a surgical indication according to the AHA, AATS, ACC, CCS and ESC guidelines. Description Aorta is an easy-to-use and comprehensive guide to individualized indications for aortic surgery. Aorta aims to provide clinicians caring for patients with aortic pathologies with patient-specific recommendations for aortic surgery based on the American Heart Association AHA, American Association for Thoracic Surgeons AATS, American College of Cardiology ACC, Canadian Cardiovascular Society CCS and European Society of Cardiology ESC guidelines on aortic diseases. Aorta is the ultimate pocket tool you need when making “grey area” decisions about recommending your patient for surgery. Key features - Guides the user through a set of essential questions for clinical decision-making - Provides a clear recommendation for clinicians caring for specific patients How it works The mechanism is really simple: you fill the form asking informations about your patient (size of the Ascending aorta or root aneurysm). After you submit the form, the application analyze your answers and will display your recommendations about aortic surgery depending on your patient conditions. So it can recommend you an aortic replacement or to make an aggressive follow up depending on the ascending aorta size or if your patient has family history of aortic dissection. The indications given by the applications are based on aortic surgery guidelines from AHA, ACC, AATS, STS, CCS and ESC.

For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy. The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER. Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.